Study of Human Botulism Immunoglobulin in Infants With Botulism
Status:
Completed
Trial end date:
1998-06-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine the safety of human botulism immune globulin (BIG) in patients with
infant botulism by monitoring side effects (e.g., rash, fever, hypotension, and anaphylaxis).
II. Assess the efficacy of BIG in these patients by monitoring disease severity, incidence of
complications (respiratory arrest, aspiration, pneumonia, etc.), and length of hospital stay.